{
  "nctrialId": "HC-1895",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of CAN-456 (receptor antagonist) in Patients With Hemophilia A",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of CAN-456 (receptor antagonist) in Patients With Hemophilia A",
  "sponsor": "Montreal Heart Institute",
  "indication": "Hemophilia A",
  "phase": "Phase 2",
  "fileName": "HC-1895.json",
  "fileSize": 291837,
  "date": "2024-09-07",
  "completionDate": "2025-11-29",
  "drugName": "CAN-456 (receptor antagonist)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of CAN-456 (receptor antagonist) in patients with Hemophilia A. The study will enroll approximately 447 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-74 years\n- Confirmed diagnosis of Hemophilia A\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}